NeuroSense Therapeutics Ltd (NRSN) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial PR...

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following...

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS:...

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire CAMBRIDGE...

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass., June 21...

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development...

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine...

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically...

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE...